Self-Assembling Matrix Forming Gel to Prevent Stricture Formation

Status Recruiting

Clinical Trial Summary

The study is designed as a multicenter prospective registry study evaluating the efficacy of the self-assembling peptide in the prevention of stricture formation after endoscopic resection as part of standard medical care. No experimental interventions will be performed.

Clinical Trial Description

In recent years, endoscopic resection by endoscopic mucosal resection(EMR) or endoscopic submucosal dissection(ESD) has become standard practice for the removal of superficial neoplasia (precancerous lesions and early cancer) throughout the gastrointestinal tract. These procedures are associated with lower morbidity and mortality when compared to conventional surgery. Nonetheless, stricture formation following endoscopic resection of gastrointestinal lesions is a well-known risk, particularly in the esophagus. The main risk factor for esophageal stricture formation following EMR/ESD is resection size, with this increasing with the length and extent of the circumferential excision, reaching 100% stricture formation when the entire circumference is involved. Stricture formation is associated with significant morbidity and increasing health care utilization, as multiple endoscopies are often required as part of the management of these difficult to treat strictures. Recently, a self-assembling peptide (SAP) forming gel (Purastat; 3D Matrix, Ltd, Tokyo, Japan) has been approved by the Food and Drug Administration (FDA) as an agent that that promotes healing, which may potentially reduce the risk of stricture formation. Initial small studies from Europe appear to show benefit but the magnitude of the effect has not been well defined. Furthermore, large prospective US based studies are currently lacking. Therefore, the aim of this study is to assess the efficacy of this novel SAP gel in the prevention of stricture formation after endoscopic resection in high-risk patients as utilized as part of clinically indicated standard patient care. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05581173
Study type	Observational [Patient Registry]
Source	AdventHealth
Contact	Dennis Yang, MD
Phone	407-303-2570
Email	Dennis.Yang.MD@adventhealth.com
Status	Recruiting
Phase
Start date	September 19, 2022
Completion date	March 2027

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04372784` - Cryoablation for Benign Gastrointestinal Anastomotic Strictures	N/A
Terminated	`NCT04406428` - NKI Therapy Compared to Usual Care of Recurrent Esophagogastric Anastomotic Strictures	N/A
Recruiting	`NCT00551824` - Evaluation of Topical Mitomycin C as Adjuvant Drug to Esophageal Dilation in Children	N/A
Completed	`NCT04284826` - Mitomycin-C Injection Therapy in Refractory Esophageal Stricture	N/A
Terminated	`NCT03898661` - Collagenase Clostridium Histolyticum for Refractory Iatrogenic Esophageal Strictures	Early Phase 1
Withdrawn	`NCT04730076` - Balloon Dilation Methods for Benign Esophageal Stricture	N/A
Active, not recruiting	`NCT03885310` - INGEST I Pilot Study	N/A
Completed	`NCT02069847` - Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy	Phase 2
Completed	`NCT03039608` - Effect of a Combination of Local Steroid Injection With Oral Steroid Administration for the Prevention on Esophageal Stricture After Endoscopic Submucosal Dissection for Early Esophageal Neoplasm	N/A
Terminated	`NCT02354716` - EndoFLIP Use in Upper GI Tract Stenosis
Recruiting	`NCT05561114` - Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus	Phase 3
Not yet recruiting	`NCT04524897` - The Use of Triamcinolone Injection in Treatment of Refractory Benign Esophageal Stricture in Children	Phase 4
Not yet recruiting	`NCT04221867` - Feasibility and Therapeutic Potential of Free Fat Grafts in the Treatment of Esophageal Strictures (ESOGRAFT)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.